Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome

This publication has 17 references indexed in Scilit:

• A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma
  Cancer, 1998
• Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1993
• Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer
  Cancer, 1993
• The relationship of p53 immunostaining to survival in carcinoma of the lung
  British Journal of Cancer, 1992
• p53, guardian of the genome
  Nature, 1992
• Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer
  Japanese Journal of Cancer Research, 1991
• Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
  Science, 1990
• Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
  Proceedings of the National Academy of Sciences, 1990
• The cellular oncogene p53 can be activated by mutagenesis
  Nature, 1985
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958